Table 1 Disease progression in sPD patients within 10 years after biopsy

From: A reversible state of hypometabolism in a human cellular model of sporadic Parkinson’s disease

Time of biopsy

Clinical changes ~10 years after biopsy

Patient ID

Gender

Years of illness

Δ H&Y

Δ UPDRS III [points]

Δ L-Dopa equivalent [mg]

Δ ADL

J2C

m

3

3

24

400

−0.6

M89

m

3

3

53

1563

−0.6

C99

m

7

2.5

36

610

−0.5

R66

m

3

Follow-up not available

AY6

M

4

1

−1

800

−0.2

PX7

M

1

1

0

1900

−0.1

88H

F

6

2

7

640

−0.3

  1. Left: Description of sPD patients at the timepoint of skin biopsy (Gender, and time in years between sPD diagnosis and tissue biopsy). Right: Long-term history of sPD patients. Changes in the Hoehn&Yahr scale (ΔH&Y), in motor examinations (Part III) according to the Unified Parkinson Disease Rating Scale (ΔUPDRS III), medication requirement (ΔL-Dopa equivalent), and activities of daily living (ΔADL) monitored within 9–12 years after skin biopsy.